Suppr超能文献

临床病例报告:骨质石化症。

Case Report of Clinical Vignette: Osteopetrosis.

作者信息

Moore John B, Hoang Thanh D, Shwayhat Alfred F

机构信息

Division of Endocrinology, Department of Medicine, Naval Medical Center San Diego, 34800 Bob Wilson Drive, San Diego, CA 92134-3300.

出版信息

Mil Med. 2017 Mar;182(3):e1886-e1888. doi: 10.7205/MILMED-D-16-00234.

Abstract

INTRODUCTION

Osteopetrosis is a connective tissue disorder resulting from abnormally dense bone predisposing patients to fracture. The clinical pattern of fractures across time and space as well as suggestive radiographic findings usually raises diagnostic suspicion. Multiple genetic mutations resulting in dysfunctional osteoclasts have been implicated in the pathogenesis of osteopetrosis with variable inheritance patterns. In severe cases, usually inherited in an autosomal recessive pattern, the medullary cavity important in the production of normal blood cell progenitors is replaced by defective endochondral bone, leading to pancytopenia and consequential extramedullary hematopoiesis.

MATERIALS AND METHODS

This is a case report from a patient presenting to Naval Medical Center San Diego, a large Military Treatment Facility constituting a regional referral center for Navy Medicine West and serving approximately 250,000 eligible patients with more than 6,200 military and civilian staff. The genetic analysis was performed by Connective Tissue Gene Tests (CTGT) using the CTGT Osteopetrosis NextGen sequencing panel, consisting of 13 genes associated with osteopetrosis. A literature review was performed using PUBMED and Google Scholar to identify information on osteopetrosis and mutation implications.

RESULTS

We present a 19-year-old male with clinical osteopetrosis resulting from compound heterozygosity of several mutated alleles within the PLEKHM1 gene, which is important to endosomal and lysosomal vesicular function. To date, most mutations discovered involve genes coding for intracellular enzymes, like carbonic anhydrase, or cell surface transporters, such as the osteoclast H-ATPase proton pump and the chloride channel, engaged in the acidification of bone at the interface of the osteoclastic ruffled border and the bone matrix. This case represents one of the few reports of inherited defects within the PLEKHM1 gene, resulting in defective osteoclastic ruffled border formation and consequential inadequate bone resorption.

CONCLUSIONS

This patient's lack of hematologic deficiencies and survival into adulthood portend an improved long-term prognosis and may infer prognostic insight in future cases with similar genetic abnormalities. In patients presenting with skeletal abnormalities and pathologic fractures in early adulthood, the clinician should consider osteopetrosis as a potential explanatory mechanism. Genetic characterization can elucidate cellular pathophysiology and potentially guide treatment modalities. Patients are typically managed with lifestyle adjustments limiting traumatic fracture and antiresorptive medications, typified by the bisphosphonate class. Since osteoclasts derive from a hematopoietic precursor, the only definitive curative therapy present is hematopoietic stem cell transplant. In the future, novel genomic level modulation may confer the ability to correct underlying point mutations and spare individuals from the morbidity associated with bone marrow transplant.

摘要

引言

骨硬化症是一种结缔组织疾病,由异常致密的骨骼引起,使患者易发生骨折。骨折在时间和空间上的临床模式以及具有提示性的影像学表现通常会引发诊断怀疑。多种导致破骨细胞功能失调的基因突变与骨硬化症的发病机制有关,其遗传模式各不相同。在严重的情况下,通常以常染色体隐性模式遗传,对正常血细胞祖细胞产生至关重要的髓腔被有缺陷的软骨内骨取代,导致全血细胞减少和随之而来的髓外造血。

材料与方法

这是一份来自一名患者的病例报告,该患者前往圣地亚哥海军医疗中心就诊,该中心是一家大型军事治疗机构,是海军医学西部的区域转诊中心,为约25万名符合条件的患者以及6200多名军事和文职人员提供服务。基因分析由结缔组织基因检测(CTGT)使用CTGT骨硬化症二代测序面板进行,该面板由13个与骨硬化症相关的基因组成。使用PUBMED和谷歌学术进行文献综述,以确定有关骨硬化症和突变影响的信息。

结果

我们报告一名19岁男性患有临床骨硬化症,其病因是PLEKHM1基因内多个突变等位基因的复合杂合性,该基因对内体和溶酶体囊泡功能很重要。迄今为止,发现的大多数突变涉及编码细胞内酶(如碳酸酐酶)的基因,或细胞表面转运蛋白(如破骨细胞H-ATPase质子泵和氯离子通道),这些转运蛋白参与破骨细胞皱襞边缘与骨基质界面处的骨酸化过程。该病例是PLEKHM1基因遗传性缺陷的少数报告之一,导致破骨细胞皱襞边缘形成缺陷,进而导致骨吸收不足。

结论

该患者缺乏血液学缺陷并存活至成年,预示着长期预后改善,并可能为未来具有类似基因异常的病例提供预后见解。对于成年早期出现骨骼异常和病理性骨折的患者,临床医生应将骨硬化症视为一种潜在的解释机制。基因特征分析可以阐明细胞病理生理学,并可能指导治疗方式。患者通常通过限制创伤性骨折的生活方式调整和抗吸收药物(以双膦酸盐类为代表)进行管理。由于破骨细胞源自造血前体,目前唯一确定的治愈性疗法是造血干细胞移植。未来,新的基因组水平调节可能使纠正潜在的点突变成为可能,并使个体免受与骨髓移植相关的疾病困扰。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验